You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-CD20 antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a Trial in Heidelberg (Standard, Experimental)

Recruiting
  • Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
  • Standard
  • Experimental
  • Heidelberg, Germany
    University Hospital Heidelberg
Jul 10, 2022

IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral Trial in Boston (Acalabrutinib, Rituximab)

Recruiting
  • IgM MGUS
  • +2 more
  • Boston, Massachusetts
  • +1 more
Nov 14, 2022

Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 20, 2022

Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia Trial in Beijing (combination of a

Recruiting
  • Autoimmune Hemolytic Anemia
  • Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
  • combination of a single dose anti-CD20 antibody and bortezomib
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 12, 2021

Primary Membranous Nephropathy Trial in Beijing (B007)

Not yet recruiting
  • Primary Membranous Nephropathy
  • Beijing, China
    Peking university first hospital
Dec 20, 2022

Primary Immune Thrombocytopenia (ITP) Trial in Tianjin (TPO-RAs, TPO-RAs combining anti-CD 20 mAb)

Not yet recruiting
  • Primary Immune Thrombocytopenia (ITP)
  • TPO-RAs
  • TPO-RAs combining anti-CD 20 monoclonal antibody
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Feb 7, 2023

Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular

Not yet recruiting
  • Nodular Lymphocyte Predominant Hodgkin Lymphoma
  • +2 more
  • Biopsy
  • +9 more
  • (no location specified)
Jun 1, 2023

Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)

Withdrawn
  • Leukemia
  • Stem Cell Transplantation
  • Munich, Bavaria, Germany
    3. Medizinische Klinik, Klinikum rechts der Isar der TU München
Dec 5, 2022

Thrombotic Thrombocytopenic Purpura Trial (Caplacizumab, Corticosteroids, anti-CD20 antibody)

Not yet recruiting
  • Thrombotic Thrombocytopenic Purpura
  • (no location specified)
Aug 8, 2022

B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

Not yet recruiting
  • B-cell Non-Hodgkins Lymphoma (B-NHL)
  • (no location specified)
Jan 5, 2023

Membranous Nephropathy Trial in Bergamo, Ranica (MOR202)

Recruiting
  • Membranous Nephropathy
  • Bergamo, BG, Italy
  • +1 more
Mar 4, 2022

Non-Hodgkin's Lymphoma Trial in New York, Philadelphia, Houston (hA20-humanized anti-CD20 antibody)

Completed
  • Non-Hodgkin's Lymphoma
  • hA20-humanized anti-CD20 antibody
  • New York, New York
  • +2 more
Aug 12, 2021

Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)

Not yet recruiting
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Sep 20, 2023

Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial

Not yet recruiting
  • Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
  • Polymorphic Post-Transplant Lymphoproliferative Disorder
  • Biopsy
  • +5 more
  • New Brunswick, New Jersey
  • +2 more
Mar 23, 2023

B-cell Lymphoma, Chronic Lymphocytic Leukaemia, Waldenström Macroglobulinemia Trial in United Kingdom (BI-1206 single agent dose

Completed
Has Results
  • B-cell Lymphoma
  • +2 more
  • BI-1206 single agent dose escalation phase
  • +3 more
  • Leicester, England, United Kingdom
  • +4 more
Jun 17, 2021

Lymphoma, Non-Hodgkin Trial in Mainz (Obinutuzumab and Pixantrone)

Completed
  • Lymphoma, Non-Hodgkin
  • Obinutuzumab and Pixantrone
  • Mainz, RLP, Germany
    Department of Hematology, Oncology and Pneumology; University Me
Mar 30, 2022

Immune Thrombocytopenia, Treatment Trial in Tianjin (Obinutuzumab Injection [Gazyva])

Not yet recruiting
  • Immune Thrombocytopenia
  • Treatment
  • Obinutuzumab Injection [Gazyva]
  • Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023

Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma Trial in Duarte

Not yet recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +2 more
  • Biopsy
  • +8 more
  • Duarte, California
    City of Hope Medical Center
May 15, 2023

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 5, 2023

Immune Thrombocytopenia, Treatment Trial in Tianjin (Obinutuzumab Injection [Gazyva])

Not yet recruiting
  • Immune Thrombocytopenia
  • Treatment
  • Obinutuzumab Injection [Gazyva]
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Oct 17, 2023

Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma (MZL)
  • Chiang Mai, Thailand
    Chiang Mai University
Nov 20, 2023

Follicular Lymphoma (FL) Trial in Noblesville (Odronextamab, Rituximab, Cyclophosphamide)

Recruiting
  • Follicular Lymphoma (FL)
  • Noblesville, Indiana
    Investigative Clinical Research of Indiana
Oct 18, 2023

Follicular Lymphoma (FL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)

Recruiting
  • Follicular Lymphoma (FL)
  • Westbury, New York
    Clinical Research Alliance Inc
Oct 13, 2023